Conduit Pharmaceuticals Announces Advancements in Lupus Treatment Research
March 28, 2025
News
New Study Identifies Potential Biomarkers for Predicting Effectiveness of Mesenchymal Stem Cell Transplantation Therapy in People with Systemic Lupus Erythematosus
March 24, 2025
News
FDA Accepts Supplemental Biologics License Application for Gayzva for Treatment of Lupus Nephritis
March 5, 2025
News
Conduit Pharmaceuticals Partners with Charles River Laboratories to Evaluate AZD1656 for Lupus Treatment
February 24, 2025
News
New Study Finds Anifrolumab In Addition to Standard of Care Treatment is Effective at Reducing Organ Damage Accumulation
February 21, 2025
News
UPDATE: Investigational CAR-T Cell Therapy ADI-001 Receives FDA Fast Track Designation for Refractory Systemic Lupus Erythematosus with Extrarenal Involvement
February 7, 2025
News
UPDATE: Gazyva® Shows Superiority Over Standard Therapy for People with Active Lupus Nephritis
February 7, 2025
News
Allogene Therapeutics’ ALLO-329 Received FDA IND Clearance for Autoimmune Disease Trial
February 3, 2025
News
Investigator-initiated Study of CNTY-101, for People with Autoimmune Diseases, Including Systemic Lupus Erythematosus and Lupus Nephritis Announced
January 24, 2025
News
UPDATE: Phase 1 Trial Begins for Investigational Therapy, CB-010, for Lupus Nephritis Treatment
January 14, 2025
News
IGM Biosciences Halts Development of Two Investigational Treatments for People with Autoimmune and Inflammatory Diseases
January 10, 2025
News
New Study Highlights Evidence Gaps and Under-Representation in Lupus Nephritis Clinical Trials
January 9, 2025
News